View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Reed’s Schedules Fourth Quarter & Full Year 2025 Conference Call for M...

Reed’s Schedules Fourth Quarter & Full Year 2025 Conference Call for March 25 at 8:30 a.m. ET NORWALK, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, will host a conference call on Wednesday, March 25, 2026, at 8:30 a.m. Eastern time to discuss its financial results for the three and twelve months ended December 31, 2025. The Company’s results will be reported in a press release prior to the call. Reed’s management will host the conference call, fol...

 PRESS RELEASE

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial...

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential firs...

 PRESS RELEASE

Espey Announces Regular Quarterly Dividend of $0.25 Per Share

Espey Announces Regular Quarterly Dividend of $0.25 Per Share SARATOGA SPRINGS, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Espey Mfg. & Electronics Corp. (NYSE AMERICAN: ESP) has declared a regular quarterly dividend of $0.25 per share. The dividend will be payable on March 27, 2026 to all shareholders of record on March 20, 2026. Espey's primary business is the development, design, and production of specialized military and industrial power supplies/transformers. The Company can be found on the Internet at   For further information, contact Ms. Kaitlyn O’Ne...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

MISTRAS Group Issues Clarification Regarding Diluted EPS Excluding Spe...

MISTRAS Group Issues Clarification Regarding Diluted EPS Excluding Special Items (Non-GAAP) Referenced During Q4 2025 Earnings Call PRINCETON JUNCTION, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, issues clarification regarding diluted EPS Excluding Special Items (Non-GAAP). During MISTRAS Group’s Q4 2025 earnings conference call held on March 5, 2026, management inadvertently stated during the prepared remarks that the Company’s Diluted EPS Excluding Special Item...

 PRESS RELEASE

MISTRAS Announces Fourth Quarter and Full Year 2025 Results

MISTRAS Announces Fourth Quarter and Full Year 2025 Results Solid Quarterly Revenue Growth of 5.1%,with an Expansion in Gross Profit Margin of 190 Basis Points,Generating Net Income of $3.9 million and Earnings Per Diluted Share of $0.12, Achieving Record Fourth Quarter Adjusted EBITDA of $24.8 million PRINCETON JUNCTION, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), a global leader in technology-enabled industrial asset integrity and testing solutions, reported financial results for its fourth quarter and twelve months ended December 31, 2025. Fourth Quarter ...

 PRESS RELEASE

Cellectar Biosciences Reports Financial Results for Year Ended 2025 an...

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NAS...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Cellectar Biosciences to Report Full Year Financial Results and Host a...

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Wednesday, March 4, 2026Time:8:30 ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 21, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 20, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

American Coastal Insurance Corporation Announces the Appointment of Tr...

American Coastal Insurance Corporation Announces the Appointment of Troy Crawford as Chief Underwriting Officer ST. PETERSBURG, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that Troy Crawford, MBA, CPCU, CLU, was appointed as Chief Underwriting Officer of ACIC. Crawford was appointed as Chief Underwriting Officer of AmCoastal in January 2025, overseeing underwriting strategy, risk selectio...

 PRESS RELEASE

American Coastal Insurance Corporation Reports Financial Results for I...

American Coastal Insurance Corporation Reports Financial Results for Its Fourth Quarter and Year Ended December 31, 2025 Company to Host Quarterly Conference Call at 5:00 P.M. ET on February 19, 2026The information in this press release should be read in conjunction with an earnings presentation that is available on the Company's website at . ST. PETERSBURG, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- February 19, 2026: American Coastal Insurance Corporation (Nasdaq: ACIC) ("ACIC" or the "Company"), a property and casualty insurance holding company, today reported its financial results for ...

 PRESS RELEASE

MISTRAS Group Announces Conference Call to Discuss Fourth Quarter Resu...

MISTRAS Group Announces Conference Call to Discuss Fourth Quarter Results on March 5, 2026 PRINCETON JUNCTION, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, March 5, 2026, at 9:00 am Eastern Time to present its results for the fourth quarter of 2025. A press release with the fourth quarter results will be issued after the close of market on Wednesday, March 4, 2026. To listen to the live webcast of the conference call, visit the Investor Relations section of MISTRAS Group’s website at . Individuals wishing to partici...

 PRESS RELEASE

Cellectar Biosciences Expands Global Intellectual Property Estate

Cellectar Biosciences Expands Global Intellectual Property Estate Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) for Iopofosine I 131 as a Treatment for Waldenström Macroglobulinemia FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the trea...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 13, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

vTv Therapeutics to Participate in Upcoming Investor Conferences

vTv Therapeutics to Participate in Upcoming Investor Conferences HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Thursday, February 26, 2026Time: 11:20 AM ETFormat: Presentat...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch